65,437 trials
Renal Transplantation
Primary: Renal Function Assessed by Measured GFR (mGFR) — 46.02; 48.00; 46.60 mL/min/1.73m^2 — p=0.6332
Nicotine Dependence
Primary: Percent Change BOLD Signal — 0.48; 0.61 BOLD Signal Change (3-back minus 0-back)
Post Traumatic Stiffness
Primary: Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire — 27; 54 Scores on a Scale (0-100) — p=0.06
Shingles
Primary: Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group — 1.994; 6.596 number of HZ cases/1000 person-years — p=<.001
Inflammatory Bowel Disease · Crohn's Disease
Primary: Cost of Illness in Participants With Crohn's Disease — 6088.40; 6169.62; 5594.00; 5825.80 Euros
Gastroesophageal Reflux
Primary: Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR. — 88 percent of…
Low Back Pain
Primary: Roland Morris Disability Questionnaire — 9; 9 units on a scale (0-24) — p=0.05
Fungal Infection
Primary: Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment — 6; 32; 11; 10 Participants
Systemic Mastocytosis
Primary: Number of Participants With Objective Response — 0 Participants
Type 1 Diabetes
Primary: Change in A1c From Baseline to 26 Weeks — -0.72; -0.58 Percent glycated hemoglobin
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2.407; 2.122 ng/mL
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
Encephalitis · Japanese Encephalitis
Primary: Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose — 194; 191 Participants
Urinary Tract Infection
Primary: Clinical Cure — 140; 123; 10; 27 participants
Post-Operative Nausea and Vomiting
Primary: Number of Patients With no Vomiting — 61; 69 participants